188 related articles for article (PubMed ID: 10381106)
1. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.
Groll AH; Gonzalez CE; Giri N; Kligys K; Love W; Peter J; Feuerstein E; Bacher J; Piscitelli SC; Walsh TJ
J Antimicrob Chemother; 1999 Jan; 43(1):95-103. PubMed ID: 10381106
[TBL] [Abstract][Full Text] [Related]
2. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Gonzalez CE; Groll AH; Giri N; Shetty D; Al-Mohsen I; Sein T; Feuerstein E; Bacher J; Piscitelli S; Walsh TJ
Antimicrob Agents Chemother; 1998 Sep; 42(9):2399-404. PubMed ID: 9736570
[TBL] [Abstract][Full Text] [Related]
5. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
6. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.
Wallace TL; Paetznick V; Cossum PA; Lopez-Berestein G; Rex JH; Anaissie E
Antimicrob Agents Chemother; 1997 Oct; 41(10):2238-43. PubMed ID: 9333054
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.
Groll AH; Petraitis V; Petraitiene R; Field-Ridley A; Calendario M; Bacher J; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 1999 Oct; 43(10):2463-7. PubMed ID: 10508025
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
9. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.
Petraitis V; Petraitiene R; Lin P; Calis K; Kelaher AM; Muray HA; Mya-San C; Mickiene D; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2005 Apr; 49(4):1642-5. PubMed ID: 15793161
[TBL] [Abstract][Full Text] [Related]
13. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
[TBL] [Abstract][Full Text] [Related]
14. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Denning DW; Warn P
Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of experimental invasive pulmonary aspergillosis in rats with liposomal amphotericin B].
Matsuda H; Kohno S; Miyazaki Y; Mitsutake K; Tanaka K; Maesaki S; Iwamoto M; Hashimoto A; Kaku M; Koga H
Kansenshogaku Zasshi; 1993 Feb; 67(2):102-9. PubMed ID: 8468494
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.
Allende MC; Lee JW; Francis P; Garrett K; Dollenberg H; Berenguer J; Lyman CA; Pizzo PA; Walsh TJ
Antimicrob Agents Chemother; 1994 Mar; 38(3):518-22. PubMed ID: 8203848
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.
Walsh TJ; Garrett K; Feurerstein E; Girton M; Allende M; Bacher J; Francesconi A; Schaufele R; Pizzo PA
Antimicrob Agents Chemother; 1995 May; 39(5):1065-9. PubMed ID: 7625790
[TBL] [Abstract][Full Text] [Related]
18. Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.
Petraitis V; Petraitiene R; Solomon J; Kelaher AM; Murray HA; Mya-San C; Bhandary AK; Sein T; Avila NA; Basevicius A; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Apr; 50(4):1510-7. PubMed ID: 16569871
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.
van de Sande WW; van Vianen W; ten Kate MT; Vissers J; Laurijsens J; Tavakol M; Rijnders BJ; Mathot RA; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2008 Apr; 52(4):1345-50. PubMed ID: 18195059
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
